Advertisement

CHEST Physician

Make CHEST Physician® a trusted source
  • Top reads from the CHEST journal portfolio – February 2025

    Top reads from the CHEST journal portfolio – February 2025

    Read commentary of studies on oronasal CPAP for OSA, the impact of pirfenidone on IPF, and extracorporeal membrane oxygenation for high-risk PE.


  • FDA grants clearance for SIMEOX 200 for patients with chronic lung disease

    FDA grants clearance for SIMEOX 200 for patients with chronic lung disease

    The approval offers providers an alternative to traditional airway clearance therapies for patients with chronic lung diseases such as bronchiectasis, COPD, and cystic fibrosis.


  • Updated GOLD report includes significant clinical implications for COPD management

    Updated GOLD report includes significant clinical implications for COPD management

    Gerard J. Criner, MD, FCCP, a member of the GOLD science committee, said one notable change was the adoption of race-neutral algorithms and equations in predictive values for lung function testing and measuring lung impairment.



  • Consequences of wildfire smoke exposure extend beyond local area

    Consequences of wildfire smoke exposure extend beyond local area

    In a recent study, Mary E. Maldarelli, MD, and colleagues demonstrated that wildfires can increase health risks even from thousands of miles away.


  • Rethinking tobacco use to include all forms of nicotine delivery

    Rethinking tobacco use to include all forms of nicotine delivery

    Frank Leone, MD, MS, FCCP, said clinicians must reframe how they think about tobacco product use—and how to treat it.


  • New pulse oximeter recommendations make progress toward accuracy across skin tones

    New pulse oximeter recommendations make progress toward accuracy across skin tones

    Aaron Baugh, MD, discussed how the recent FDA draft guidance on pulse oximeter performance testing should improve accuracy in patients with darker skin tones.


  • Expanding treatments for COPD management

    Expanding treatments for COPD management

    Recent FDA approval of dupilumab and ensifentrine marks significant progress in therapies targeting inflammation, lung function, and symptom relief for patients with COPD.


  • From decline to resurgence: Rise and response to US and global TB burden

    From decline to resurgence: Rise and response to US and global TB burden

    TB prevalence has been rising since 2019, driven by reduced precautions and conflicts, though shorter treatments and strategic plans offer hope for elimination.



  • Artificial intelligence and its application in interstitial lung disease

    Artificial intelligence and its application in interstitial lung disease

    AI shows promise in improving ILD diagnosis, prognosis, and treatment decisions by analyzing complex data and patterns, though certain limitations hinder its clinical adoption.


  • Supporting vaccinations in the name of public health

    Supporting vaccinations in the name of public health

    CHEST supports the fundamental responsibility of a public health system to seek out and apply evidence-based medicine in the development of sound policies essential to preventing illness.